Erratum: Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor negative breast cancer (British Journal of Cancer (2012) 106: (1453-1459) DOI: 10.1038/bjc.2012.98);Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor-negative breast cancer

British Journal of Cancer

Volumn 106, Issue 8, 2012, Pages 1453-1459

  Ohotski, J ^a   Long, J S ^a   Orange, C ^b   Elsberger, B ^b   Mallon, E ^b   Doughty, J ^b   Pyne, S ^a   Pyne, N J ^a   Edwards, J ^c  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

extracellular signal regulated kinase; HER2; oestrogen receptor; sphingosine 1 phosphate; sphingosine 1 phosphate receptor 4; sphingosine kinase

Indexed keywords

4 (2,6 DICHLORO 4 PYRIDINYL) 1 (1,3 DIMETHYL 4 ISOPROPYL 1H PYRAZOLO[3,4 B]PYRIDIN 6 YL)SEMICARBAZIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOTRANSFERASE INHIBITOR; SKI [2 (4 HYDROXYANILINO) 4 (4 CHLOROPHENYL)THIAZOLE]; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR 4; SPHINGOSINE KINASE 1; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER GROWTH; CELL MIGRATION; CLINICAL ASSESSMENT; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE SPECIFIC SURVIVAL; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84859648774     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.352     Document Type: Erratum

References (16)

1. Alderton F, Rakhit S, Kong K-C, Palmer T, Sambi S, Pyne S, Pyne NJ (2001) Tethering of the platelet-derived growth factor beta receptor to G-protein coupled receptors: a novel platform for integrative signalling by these receptor classes in mammalian cells. J Biol Chem 276: 28578-28585 (Pubitemid 37391573)
2. Alvarez SE, Harikumar KB, Hait NC, Allegood J, Strub GM, Kim EY, Maceyka M, Jiang H, Luo C, Kordula T, Milstein S, Speigel S (2010) Sphingosine 1-phosphate is a missing co-factor for the E3 ligase TRAF2. Nature 465: 1084-1088
3. Borg A, Tandon AK, Sigurdsson H (1990) HER2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 50: 4332-4337 (Pubitemid 20225674)
4. Fisher KE, Pop A, Koh W, Anthis NJ, Saunders WB, Davis GE (2006) Tumour cell invasion of collagen matrices requires coordinate lipid agonist-induced G protein and membrane-type matrix metalloproteinase- 1-dependent signalling. Mol Cancer 5: 69
5. Kajo K, Zubor P, Barthova M, Plank L (2007) Scoring index for prediction of HER2 status in the invasive breast carcinoma. Exp Oncol 29: 281-286 (Pubitemid 351236317)
6. Lim KG, Tonelli F, Li Z, Lu X, Bittman R, Pyne S, Pyne NJ (2011) FTY720 analogues as sphingosine kinase 1 inhibitors: Enzyme inhibition kinetics allosterism proteasomal degradation and actin rearrangement in MCF-7 breast cancer cells. J Biol Chem 286: 18633-18640
7. Long JS, Edwards J, Watson C, Tovey S, Mair K, Schiff R, Natarajan V, Pyne NJ, Pyne S (2010a) Sphingosine kinase 1 induces tolerance to human epidermal growth factor receptor 2 and prevents formation of a migratory phenotype in response to sphingosine 1-phosphate in estrogen receptor positive breast cancer cells. Mol Cell Biol 30: 3827-3841
8. Long JS, Fujiwara Y, Edwards J, Tannahill C, Tigyi G, Pyne S, Pyne NJ (2010b) Sphingosine 1-phosphate 4 uses HER2 (ErbB2) to regulate extracellular signal regulated kinase-1/2 in MDA-MB-453 breast cancer cells. J Biol Chem 285: 35957-35966
9. Loveridge C, Tonelli F, Leclecq T, Lim KG, Long S, Berdyshev E, Tate RJ, Natarajan V, Pitson Pyne NJ, Pyne S (2010) The sphingosine kinase 1 inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole induces proteosomal degradation of sphingosine kinase 1 in mammalian cells. J Biol Chem 285: 38841-38852
10. Pyne NJ, Pyne S (2010) Sphingosine 1 phosphate and cancer. Nat Rev Cancer 10: 489-503
11. Ruckäberle E, Rody A, Engels K, Gaetje R, von Minckwitz G, Schiffmann S, Grösch S, Geisslinger G, Holtrich U, Karn T, Kaufmann M (2008) Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat 112: 41-52
12. Takabe K, Paugh SW, Milstien S, Spiegel S (2008) 'Inside-out' signalling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev 60: 181-195 (Pubitemid 351962008)
13. Tonelli F, Lim KG, Loveridge C, Long J, Pitson SM, Tigyi G, Bittman R, Pyne S, Pyne NJ (2010) FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promotes its proteasomal degradation in human pulmonary artery smooth muscle breast cancer and androgen-independent prostate cancer cells. Cell Signal 22: 1536-1542
14. Van Brocklyn JR, Jackson CA, Pearl DK, Kotur MS, Snyder PJ, Prior TW (2005) Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: role of sphingosine kinase isoforms in growth of glioblastoma cell lines. J Neuropathol Exp Neurol 64: 695-705 (Pubitemid 41177111)
15. 3, sphingosine kinase 1, and extracellular signal-regulated kinase-1/2 is associated with development of tamoxifen resistance in estrogen receptor-positive breast cancer patients. Am J Pathology 177: 2205-2215
16. Yamashita H, Kitayama J, Shida D, Yamaguchi H, Mori K, Osada M, Aoki S, Yatomi Y, Takuwa Y, Nagawa H (2006) Sphingosine 1-phosphate receptor expression profile in human gastric cancer cells: differential regulation on the migration and proliferation. J Surg Res 130: 80-87 (Pubitemid 43028568)